Search

Objective: This study aimed to determine the effect of tocilizumab use on mortality and the potential side effects in COVID-19 patients., Patients and Methods: The intensive care patients were divided into the tocilizumab group and the control group. Hemogram, biochemistry, acute phase reactant values, age, gender, comorbidity, and culture results were recorded on the 0th, 3rd, 7th, and 14th days. Factors affecting mortality between and within the groups and side effects were examined., Results: 32.14% of the patients were female, and 67.85% were male. The tocilizumab group had high alanine aminotransferase and potassium on day 3. On day 7, low levels of platelet, glucose, international normalized ratio, prothrombin time, and active partial thromboplastin time levels were observed. Procalcitonin, C-reactive protein, and fibrinogen levels were low on days 3 and 7. The relationship between the tocilizumab treatment and mortality was statistically not significant, although the APACHE score was low. In the tocilizumab group, the presence of additional disease and reproduction in culture significantly increased mortality., Conclusions: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.

Background: COVID-19 is a disease with high mortality worldwide, and which parameters that affect mortality in intensive care are still being investigated. This study aimed to show the factors affecting mortality in COVID-19 intensive care patients and write a model that can predict mortality., Methods: The data of 229 patients in the COVID-19 intensive care unit were scanned. Laboratory tests, APACHE, SOFA, and GCS values were recorded. CT scores were calculated with chest CTs. The effects of these data on mortality were examined. The effects of the variables were modeled using the stepwise regression method., Results: While the mean age of female (30.14%) patients was 69.1 ± 12.2, the mean age of male (69.86%) patients was 66.9 ± 11.5. The mortality rate was 69.86%. Age, CRP, D-dimer, creatinine, procalcitonin, APACHE, SOFA, GCS, and CT score were significantly different in the deceased patients than the survival group. When we attempted to create a model using stepwise linear regression analysis, the appropriate model was achieved at the fourth step. Age, CRP, APACHE, and CT score were included in the model, which has the power to predict mortality with 89.9% accuracy., Conclusion: Although, when viewed individually, there is a significant difference in parameters such as creatinine, procalcitonin, D-dimer, GCS, and SOFA score, the probability of mortality can be estimated by knowing only the age, CRP, APACHE, and CT scores. These four simple parameters will help clinicians effectively use resources in treatment., (Copyright © 2022 Elsevier Inc. All rights reserved.)